Abstract:Background: Detection and endoscopic excision of colorectal precancerous lesions (advanced adenoma, AA) has been recognized as an effective way to prevent the occurrence of colorectal cancer (CRC) and reduce CRC induced mortality. Current DNA-based (mutations or methylations) tests exhibited compromised efficiency for AA diagnosis due to the late appearance of tumor-derived DNA biomarkers into stool or blood samples during tumorigenesis. Here, by integrating metabolic biomarkers associated with tumor tissue and colorectal neoplasia related gut microbiota, we established the serum metabolites-based test and examined its ability to detect advanced adenoma patients from normal, hyperplastic polyps and low-risk adenoma individuals. Methods: Consensus participants undergoing coloscopy were enrolled in this prospective study, and the result of colonoscope examination and histopathology from biopsied lesions were used as gold standard (ChiCTR2200058078). Serum metabolites were quantified by pseudo-targeted metabolomics based on LC-MS/MS method. By integrating abundances of these serum metabolites associated with tumor tissue and colorectal neoplasia related gut microbiota, a diagnostic model was established, and its performance for detecting advanced adenoma was validated using leave-one-out cross-validation. Results: In total, 803 participants, including 178 normal individuals, 167 patients with hyperplastic polyps, 203 patients with low-risk colorectal adenoma and 255 advanced colorectal adenoma patients, were enrolled in this study and subjected to the serum metabolites-based test. The diagnostic model achieved an AUC of 0.80 (95% CI: 0.77-0.83) for advanced adenoma, with a sensitivity of 44.7% at 88.9% specificity. Additionally, we also separately analyzed its performances for advanced adenoma with different histological subtypes, achieving a sensitivity of 37.0% for tubulous adenoma and a sensitivity of 53.3% for adenoma with villous structure, respectively. As for advanced adenoma with high-grade dysplasia, the model could achieve a sensitivity of 61.2%. In comparation, sensitivities of all current tests for advanced colorectal adenoma, either fecal or blood based, were less than 45% at a similar specificity. Conclusions: Based on integrating metabolic biomarkers associated with both tumor tissue and colorectal neoplasia related gut microbiota, we developed a novel blood-based test that can detect advanced colorectal adenoma with higher accuracy than all current fecal or blood-based tests. Citation Format: Jingyuan Xiang, Longsong Li, Xingting Guo, Xiaowei Li, Kai Lin, Liuyang Yang, Xudong Dai, Enqiang Linghu, Ningli Chai. Evaluation of a serum-based test integrating tumor tissue and gut microbiome derived metabolites for diagnosis of advanced colorectal adenoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited s); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl) nr 3346.

Machine learning-based identification of colorectal advanced adenoma using clinical and laboratory data: a phase I exploratory study in accordance with updated World Endoscopy Organization guidelines for noninvasive colorectal cancer screening tests

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study

Circulating Bacterial DNA As a Tool Towards Noninvasive Biomarkers for Colorectal Adenocarcinoma and Adenoma.

Abstract 3346: Evaluation of a serum-based test integrating tumor tissue and gut microbiome derived metabolites for diagnosis of advanced colorectal adenoma

Development and Validation of Machine Learning Algorithms for Prediction of Colorectal Polyps Based on Electronic Health Records

Blood Biomarkers Panels for Screening of Colorectal Cancer and Adenoma on a Machine Learning-Assisted Detection Platform

Standard-definition White-light, High-definition White-light Versus Narrow-band Imaging Endoscopy for Detecting Colorectal Adenomas: A Multicenter Randomized Controlled Trial.

Development and validation of machine learning models for young-onset colorectal cancer risk stratification

Screening and Diagnosis of Colorectal Cancer and Advanced Adenoma by Bionic Glycome Method and Machine Learning.

Enhancing the diagnostic accuracy of colorectal cancer through the integration of serum tumor markers and hematological indicators with machine learning algorithms

Integrated analysis of colorectal neoplasia tissue and gut microbiome associated serum metabolites for diagnosis of early-stage CRC and advanced adenoma.

Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma

A 5-hydroxymethylcytosine-based non-invasive model for early detection of colorectal carcinomas and advanced adenomas: the METHOD-2 study

A 5-hydroxymethylcytosine-based noninvasive model for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma: The METHOD-2 study.

Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data

Evaluation of a sensitive blood test for the detection of colorectal advanced adenomas in a prospective cohort using a multiomics approach.

Construction and validation of machine learning models for predicting distant metastases in newly diagnosed colorectal cancer patients: A large‐scale and real‐world cohort study

Early Colorectal Cancer Detected by Machine Learning Model Using Gender, Age, and Complete Blood Count Data

Application of machine learning in the prediction of deficient mismatch repair in patients with colorectal cancer based on routine preoperative characterization